Navigation Links
e-Zassi.com Provides Industry With Online U.S. FDA Regulatory Calculator for Rapid Medical Device Technology Assessment
Date:10/20/2009

FERNANDINA BEACH, Fla., Oct. 20 /PRNewswire/ -- e-Zassi.com, the fast-growing provider of the medical device industry's first secure online decision-support and industry network, has released its powerful U.S. Regulatory Calculator as a stand-alone tool available at $375 at www.e-Zassi.com to give users an analysis of the FDA classification of up to three separate medical technologies along with a one-year membership in the e-Zassi medical device industry network.

e-Zassi.com was developed as an online industry network to allow everyone across the spectrum of medical device industry to search, match, collaborate and analyze technologies, individuals and organizations using the most advanced decision-support search engine platform that uniquely fosters deeper levels of information sharing while also protecting members from over-disclosure issues that could negatively impact intellectual properties.

The e-Zassi.com U.S. Regulatory Calculator

The e-Zassi.com U.S. Regulatory Calculator is proprietary software powered by a current database of information on classified medical devices. Anyone involved with medical devices - from researchers to engineers, technology transfer agents, business development officers, medical device companies and investors - can use the new FDA Regulatory Calculator by inputting non-confidential product attributes and physical details about their new product or technology. The e-Zassi.com U.S. Regulatory Calculator searches and provides the potential predicate codes and other critical regulatory information in just minutes, rather than more than two months, which is often how long it takes for the U.S. Food and Drug Administration to determine a product's classification.

"Because many products don't fit neatly into existing classifications, this process is often a complex and confusing first step when designing a product or making a submission to the FDA," said e-Zassi Chief Executive Officer Peter M. von Dyck, who holds numerous patents and has commercialized many new medical device technologies. Von Dyck explains that: "Not knowing the potential FDA classification early on can adversely skew the entire development, clinical trials, commercialization and capitalization plans. Understanding and navigating the regulatory environment and classification that a newer medical technology will need to conform to is one of the most essential elements of any development and commercialization plan and without this information early and throughout the development process you are in essence developing in the dark."

About e-Zassi.com

e-Zassi.com is a subscription-based online community and Software as a Service (SaaS) company that was spun off Zassi Medical Evolutions®, a privately held company with more than a decade innovating and developing in medical devices. The full suite of software tools on e-Zassi.com supports those in the medical device industry, from product development through manufacturing and distribution. Tools allow for technology transfer; business development; market and commercial analysis; due diligence & portfolio management; intellectual property and patent development; product development and financial planning; and capital acquisition via venture capital and grants. Customized memberships are available now. For more information regarding e-Zassi.com or to join the Network, please visit www.e-zassi.com or call +1.866.474.6328.

SOURCE e-Zassi.com


'/>"/>
SOURCE e-Zassi.com
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Raptor Pharmaceuticals Provides Update of Product Programs
5. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
6. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
7. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
11. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , February 10, 2016 Puerto Rico ... Puerto Rico Healthcare and Life Sciences Report 2016 ... page Puerto Rico Healthcare and Life Sciences Report 2016 ... into the fifth largest territory in the world for pharma ... device and diagnostics manufacturing, and more universities per square mile ...
(Date:2/10/2016)... , Feb. 10, 2016 Convergence ... confluence of various technologies that results in ... unavailable. These opportunities create a cyclical system ... turn, drives the development of new technologies. ... characterized by technology convergences, which are constantly ...
(Date:2/10/2016)... PRINCETON, New Jersey and OR AKIVA, ... Regentis Biomaterials Ltd., a leader ... of its Series D investment round on February 5, ... Haisco Pharmaceutical Group ("Haisco"), a leading Chinese pharmaceutical ... Medica Partners, SCP Vitalife Partners, Generali Financial Holdings and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: ... winner and inspirational speaker Jan Fox will serve as keynote speaker at the ... provide participants with tools to more effectively communicate with their own organizational staff ...
(Date:2/10/2016)... Baltimore, MD (PRWEB) , ... February 10, 2016 ... ... (ADP) to make Everseat digital self-scheduling readily available to physicians. The ... so patients can find and select appointments via Everseat’s free mobile app. , ...
(Date:2/10/2016)... Denver, Colorado (PRWEB) , ... February 10, 2016 , ... ... now, but cannabis enthusiasts in the state still face a lot of restrictions as ... “retail marijuana is intended for private, personal use” and that cannabis “may not be ...
(Date:2/10/2016)... ... February 09, 2016 , ... According to a recent ... increase in the number of patients under the age of 30. According to Southern ... in their offices, and may indicate an overall shift in the rapidly growing social ...
(Date:2/9/2016)... Fort Worth, Texas (PRWEB) , ... February 09, ... ... restoration and reconstruction firm helping businesses recover after a disaster, announced today the ... restoration service companies in Hawaii. , “Investing in like-minded companies who ...
Breaking Medicine News(10 mins):